CURRENT OBJECTIVES FOR TARGET TREATMENT OF RHEUMATOID ARTHRITIS: FROM MONOCLONAL ANTIBODIES TO BLOCKERS OF SIGNALING PATHWAYS MOLECULES

Kovalenko V.M.¹, Golovach I.Yu.², Bortkevych O.P. ³

• ¹ГУ «ННЦ «Институт кардиологии им. Н.Д. Стражеско» НАМН Украины», Киев
• ²Feofaniya Clinical Hospital, Kyiv
• ³SI «NSC «Institute of Cardiology M.D. Strazhesko» NAMS of Ukraine», Kyiv

Summary. Summary. The review article presents current approaches to drug therapy of rheumatoid arthritis (RA), new drugs evolution from the monoclonal antibody to tumor necrosis factor-α to the small molecule inhibitors. Decryption of RA pathogenesis, discovery of many new molecules and signaling pathways involved in the disease pathogenesis, enabled creation of drugs targeting specific molecules, signaling pathways and mediators activating the immune system, which affects main clinical symptoms of RA, progression mechanisms and ensures the main goal of treatment — remission. The new biological drugs that affect B-cell, co-stimulation of T-cells, as well as new targets of the pharmacological effects — small molecule inhibitors — are defined. Mechanisms of intracellular signal transduction and signaling pathways molecules are described in detail. A new potentially promising direction in rheumatoid arthritis treatment by using blockers of JAK kinase and Syk is introduced in the article.